Thursday, December 20, 2012
Emory University researchers have identified excessive daytime
sleepiness as a repurposing opportunity for flumazenil, a generic GABAA receptor
antagonist.1 Although safety issues have stymied prior attempts to
use GABAA receptor antagonists in this chronic indication, the group
thinks a new formulation could make it possible.
Path to repurposing
Although the findings point to the
potential to repurpose flumazenil, the clinically approved version of the
compound is intravenous, short lived and intended for single-injection
applications. Moreover, the drug carries a black box warning of seizure risk.
Martz, L. SciBX 5(49); doi:10.1038/scibx.2012.1275 Published online
Dec. 20, 2012
1. Rye, D.B. et al.
Sci. Transl. Med.; published online Nov. 21, 2012; doi:10.1126/scitranslmed.3004685
Contact: David B. Rye, Emory University School of Medicine, Atlanta, Ga.
2. Ahboucha, S. & Butterworth,
R.F. Metab. Brain Dis. 20, 425-437 (2005)
3. Seifritz, E. et al.
Psychopharmacology (Berl.) 120, 449-456 (1995)
4. Cortelli, P. et
al. Sleep Med. Rev. 9, 477-487 (2005)
5. Czeisler, C.A. et
al. N. Engl. J. Med. 353, 476-486 (2005)
AND INSTITUTIONS MENTIONED
Inc. (NASDAQ:CEPH), Frazer,
Healthcare, Atlanta, Ga.
University, Atlanta, Ga.
University School of Medicine,
Medical School, Boston, Mass.
Lundbeck A/S (CSE:LUN),
General Hospital, Boston,
Institute of Neurological Disorders and Stroke, Bethesda, Md.
Pharmaceutical Co. Ltd.
(Tokyo:4528; Osaka:4528), Osaka, Japan
AG (Xetra:PA8), Aachen,
Pharmaceutical Industries Ltd.
(NYSE:TEVA), Petah Tikva, Israel